Monitor for SEC effectiveness of the registration statement and any shareholder vote on increasing authorized shares. The rights offering, if completed, could provide capital but also dilute existing holders. Watch for the record date and exercise price details in the prospectus.
Price Chart
Executive Summary
Vivos Therapeutics announced its intention to file a registration statement for a proposed rights offering, where shareholders would receive transferable subscription rights to purchase common stock at a premium to market price (greater of $1.25 or 20% above market). The offering is contingent on SEC effectiveness, shareholder approval for additional authorized shares, and other conditions. This signals a capital need and potential dilution, though the premium pricing and transferability partially mitigate the impact.
Key Facts
- Proposed rights offering: each right to purchase one share at the greater of $1.25 or 20% above market price on day before record date
- Rights are transferable and expected to be listed for trading, exercisable for 9 months
- Upon exercise, holder receives a subsequent 9-month trading right at the greater of $1.75 or 40% above market
- Offering subject to SEC effectiveness, shareholder vote to increase authorized shares, board approval, and market conditions
- No assurance the offering will be completed; company reserves right to modify, postpone, or terminate
Financial Impact
Undisclosed amount; potential capital raise at premium pricing, but dilution risk if not fully subscribed. Company has $8M market cap.
Risk Factors
- Offering may be delayed, modified, or abandoned
- Shareholder approval for additional authorized shares may not be obtained
- Dilution if rights are not fully exercised by existing shareholders
- Uncertain tax treatment of rights received as a dividend
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028912 |
| Exhibit: ex99-1.htm | 0001493152-26-028912 |
| Document: 0001493152-26-028912-index-headers.html | 0001493152-26-028912 |
| Document: 0001493152-26-028912-index.html | 0001493152-26-028912 |
| Document: 0001493152-26-028912.txt | 0001493152-26-028912 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1313 (−2.52%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1313 (−6.88%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1313 (−6.61%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1313 (−8.05%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1313 (−8.05%) |
Sep 30, 2026 25d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1313 (+11.88%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1313 (−41.62%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1313 (−52.57%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1313 (+56.41%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1313 (−61.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers